Background
==========

Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for 1.3 million deaths annually \[[@B1]\]. It is defined as cancer that forms in the tissues of the lung, usually in the cells lining air passages, and is divided into two main subtypes: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is the predominant subtype form and accounts for about 85% of all lung cancers \[[@B2]\]; it is further divided by cell histology into adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma, with adenocarcinoma the currently predominant histology. Although the overall age-adjusted incidence rates for lung cancer are declining in many developed nations, lung cancer remains the leading cause of cancer-related deaths worldwide with an overall 5-year survival rate of about 15% \[[@B3]\], resulting in a significant disease burden worldwide.

The treatment of lung cancer is based on the type and stage of tumor, as well as the patient's general medical condition. For patients diagnosed with early stage disease (i.e., stages I and II), surgery offers the best option for survival and cure. Adjuvant chemotherapy is increasingly used in those with stage II disease and occasionally for those with stage IB, depending on the size of the tumor. For those with stage III lung cancer, chemoradiotherapy alone or in addition to surgery is used to treat patients; however, while treatment is administered with a curative intent, the 5-year survival for patients with regional disease is approximately 26%, which decreases to 3.9% for patients with metastatic disease \[[@B3]\]. Treatment for patients with advanced disease tends to be palliative, although extension in survival may be achieved. The standard first-line drug treatments for advanced NSCLC, neoadjuvant, adjuvant, or chemoradiotherapy, are generally based on the combination of a second- or third-generation cytotoxic drug with a platinum agent (cisplatin or carboplatin).

There are many drug therapies available for treatment of NSCLC; however, not all current therapies are suitable for use in tumors of all histologies. The results of clinical trials have indicated that drugs such as pemetrexed have greater efficacy among patients with adenocarcinoma than those with other NSCLC histologies (e.g., squamous cell carcinoma) \[[@B4]\]. Other newer agents, such as bevacizumab, are indicated for adenocarcinoma because of higher toxicities observed in patients with squamous histology \[[@B5]\]. Drugs such as erlotinib and gefitinib are not restricted by histology, but have greater efficacy among patients with epidermal growth factor receptor (EGFR) mutations \[[@B6],[@B7]\]. The frequency of EGFR mutations in patients with squamous cell carcinoma, as opposed to those with adenocarcinoma, is very low \[[@B8]\]. Therefore, histology-specific treatment options are limited for patients with squamous cell carcinoma, which accounts for about 25% of all non-small cell lung cancers \[[@B9]\].

There is thus a high unmet need for effective treatments for patients with squamous NSCLC, as disease burden is large and there is currently a lack of targeted drug therapies for NSCLC squamous cell tumors. Eli Lilly and Company is currently developing necitumumab as a first-line treatment in patients with stage IV squamous NSCLC. The current phase III study (ClinicalTrials.gov identifier: NCT00981058) is a randomized, multicenter, open-label study of gemcitabine-cisplatin chemotherapy plus necitumumab (GC + N) versus gemcitabine-cisplatin (GC) chemotherapy alone in first-line treatment of patients with stage IV squamous NSCLC. The target patient population for this trial is comprised of male and female patients with histologically or cytologically confirmed, advanced squamous NSCLC, previously untreated for metastatic disease.

The purpose of this systematic literature review and meta-analysis is to compare survival, toxicity, and quality of life outcomes of current treatment strategies with necitumumab among patients with squamous NSCLC.

Methods/Design
==============

This systematic literature review and meta-analysis (including indirect comparisons) will be conducted of treatments used in squamous NSCLC to assess the clinical efficacy, quality of life, and safety of GC + N compared to other treatments used in squamous NSCLC. To complete this objective, the following specific aims will be pursued:

1\. To conduct a systematic literature review of randomized trials of all relevant treatments used for the first-line treatment of advanced squamous NSCLC;

2\. To extract relevant data from the relevant published literature;

3\. To perform indirect and direct comparisons of GC + N to all identified comparators for the following outcomes:

3.1 Overall survival;

3.2 Progression-free survival;

3.3 Toxicity; and

3.4 Quality of life

Search strategy
---------------

Searches will be conducted in PubMed, Ovid/MEDLINE, and Embase using free text and controlled vocabulary terms (MeSH). Studies published prior to 1995 will be excluded as NSCLC histology was not clearly differentiated at that time. Studies not published in English will be excluded. Comparisons will be made across all regimens and not just limited to \"add-on\" therapies. Tables  [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, and [3](#T3){ref-type="table"} detail the specific search strategies for PubMed, Ovid, and Embase, respectively.

###### 

PubMed search strategy

      **PubMed search**                                                                                                                       
  ------------------------- ------ ---------------------------------------------------------------------------------------------------------- -----------
        Disease terms        \#1                         \"carcinoma, non small cell lung/drug therapy\" \[MeSH Terms\]                         11,135
        Design terms         \#2                           Randomized Controlled Trials as Topic \[MeSH Major Topic\]                           12,361
                             \#3                            \"randomized controlled trials as topic\" \[MeSH Terms\]                            85,095
                             \#4                                        Random Allocation \[MeSH Terms\]                                        76,843
                             \#5                                       double blind method \[MeSH Terms\]                                       118,616
                             \#6                               \"controlled clinical trial\" \[Publication Type\]                               85,642
                             \#7                              \"randomized controlled trial\" \[Publication Type\]                              344,749
                             \#8                                  \"clinical trials as topic\" \[MeSH Terms\]                                   263,513
                             \#9                                    \"clinical trial\" \[Publication Type\]                                     709,361
                             \#10                        ((\#2 or \#3 or (\#4 and (\#5 or \#8 or \#9)) or \#6 or \#7))                          509,729
                             \#11                             ((randomization and control and clinical and trial))                              10,468
                             \#12    (((randomised and control and clinical and trial) or (randomized and control and clinical and trial)))     108,134
                             \#13             ((((double or single or triple or treble) and (blind\* or mask\*) and (random\*))))               136,554
                             \#14                              (((random and allocat\*) and control\* and trial))                                4,775
                             \#15                                            (\#12 or \#13 or \#14)                                             214,899
                             \#16                                                (\#10 or \#15)                                                 527,440
                             \#17                                                (\#1 AND \#16)                                                  2,065
       Exclusion terms       \#18                                        Case report \[Title/Abstract\]                                         195,029
                             \#19                                         Review \[Publication Type\]                                          1,765,829
                             \#20                                         Letter \[Publication Type\]                                           794,012
                             \#21                                   \"systematic review\" \[Title/Abstract\]                                    39,341
                             \#22                                    \"clinical review\" \[Title/Abstract\]                                      3,144
                             \#23                                    (\#18 OR \#19 OR \#20 OR \#21 OR \#22)                                    2,734,788
                             \#24                                               (\#17 NOT \#23)                                                  1,579
   Year and language terms   \#25   ((\#24) AND (\"1995\" \[Date - Publication\]: \"2013\" \[Date - Publication\])) AND English \[Language\]     1,217

###### 

Embase search strategy

   **Embase search**                                                                                                                                                                                                                                        
  ------------------- ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------
     Design terms      \#1                                                                                            \"randomized controlled trial (topic)\"/exp                                                                                              37,931
                       \#2                                                                                                \"randomized controlled trial\"/exp                                                                                                 337,523
                       \#3                                                                                                       \"randomization\"/exp                                                                                                         61,698
                       \#4                                                                                                   \"double blind procedure\"/exp                                                                                                   115,032
                       \#5                                                                                                 \[controlled clinical trial\]/lim                                                                                                  511,199
                       \#6                                                                                                \[randomized controlled trial\]/lim                                                                                                 337,523
                       \#7                                                                                                       \"clinical trial\"/exp                                                                                                       961,450
                       \#8                                                                                                   \"clinical trial (topic)\"/exp                                                                                                    73,222
                       \#9                                                                                               \#1 OR \#2 OR \#3 OR \#4 OR \#5 OR \#6                                                                                              1,088,520
                       \#10                                                            singl\*: ab,ti OR doubl\*: ab,ti OR treb\*: ab,ti OR tripl\*: ab,ti AND (blind\*: ab,ti OR mask\*: ab,ti)                                                              174,394
                       \#11                                                                                                         \"placebo\"/exp                                                                                                           236,244
                       \#12                                                      random\* AND (clinical OR control\*) AND trial OR (placebo\* AND (\"randomly allocated\" OR (allocated AND random\*)))                                                       504,649
                       \#13                                                                                             (\#7 OR \#8) AND (\#10 OR \#11 OR \#12)                                                                                               513,722
                       \#14                                                                                                           \#9 OR \#13                                                                                                             705,098
    Exclusion terms    \#15                                                                                                    \[conference review\]/lim                                                                                                       3,863
                       \#16                                                                                                      \"case report\":ab,ti                                                                                                        256,868
                       \#17                                                                                                          \[review\]/lim                                                                                                          2,026,389
                       \#18                                                                                                          \[letter\]/lim                                                                                                           827,115
                       \#19                                                                                                  \"phase 1 clinical trial\"/exp                                                                                                    24,619
                       \#20                                                                                      \[short survey\]/lim OR \"historical article\": ab,ti                                                                                        514,714
                       \#21                                                                                                   \"systematic review\": ab,ti                                                                                                     78,920
                       \#22                                                                                                    \"clinical review\": ab,ti                                                                                                      3,904
                       \#23                                                                                   \#15 OR \#16 OR \#17 OR \#18 OR \#19 OR \#20 OR \#21 OR \#22                                                                                   3,628,070
                       \#24                                                                                                          \#14 NOT \#23                                                                                                            424,301
       Rx terms        \#25                                                                                                     \"drug therapy\"/exp/mj                                                                                                       574,153
                       \#26                                                                                                  \"treatment response\"/exp/mj                                                                                                     2,763
                       \#27                                                                                                   \"treatment outcome\"/exp/mj                                                                                                     28,936
                       \#28                                                                                                     \"drug efficacy\"/exp/mj                                                                                                      153,753
                       \#29                                                                                                  \"outcome assessment\"/exp/mj                                                                                                     9,603
                       \#30                    chemothera\* OR (\"drug\"/exp/mj AND thera\*) OR antineoplastic\* OR palliat\* OR standar\* NEAR/2 care OR support\* NEAR/2 care OR \"best supportive care\" OR best?support\* NEXT/2 care                    1,895,030
                       \#31                                                                                                       \"radiotherapy\"/exp                                                                                                        367,367
                       \#32                                                                                       \#25 OR \#26 OR \#27 OR \#28 OR \#29 OR \#30 OR \#31                                                                                       2,609,134
                       \#33                                                                                                          \#23 AND \#31                                                                                                             88,937
     Disease terms     \#34                                                            ((lung\$ OR pulmon\$) NEAR/5 (adenocarcinom\$ OR squamous OR \"large cell\" OR \"non-small cell\")): ab,ti                                                              44,817
                       \#35                                                                                                \"lung non small cell cancer\"/exp                                                                                                  52,027
                       \#36                                                                                                        metastatic: ab,ti                                                                                                          181,820
                       \#37                                                                                                         advanced: ab,ti                                                                                                           320,393
                       \#38                                                                                                          stage 3: ab,ti                                                                                                              61
                       \#39                                                                                                        \"Stage 3\": ab,ti                                                                                                          8,708
                       \#40                                                                                                          stage 4: ab,ti                                                                                                              32
                       \#41                                                                                                        \"stage 4\": ab,ti                                                                                                          5,270
                       \#42                                                                                                         stage iii: ab,ti                                                                                                             30
                       \#43                                                                                                       \"stage iii\": ab,ti                                                                                                         31,468
                       \#44                                                                                                         stage iv: ab,ti                                                                                                              41
                       \#45                                                                                                       \"stage iv\": ab,ti                                                                                                          20,205
                       \#46                                                                                                     \"stage iii/iv\": ab,ti                                                                                                          6
                       \#47                                                                                                     \"stage iii/iv\": ab,ti                                                                                                        4,552
                       \#48                                                                                                     \"stage iiib/iv\": ab,ti                                                                                                         2
                       \#49                                                                                                     \"stage iii/iva\": ab,ti                                                                                                         1
                       \#50                                                                                                        stage\* iii: ab,ti                                                                                                            32
                       \#51                                                                                                       stage\* iii\*: ab,ti                                                                                                           49
                       \#52                                                                                                        stage\* iv: ab,ti                                                                                                             41
                       \#53                                                                                                       stage\* iv\*: ab,ti                                                                                                            52
                       \#54                                                                                                        stage iii\*: ab,ti                                                                                                            47
                       \#55                                                                                                        stage iv\*: ab,ti                                                                                                             46
                       \#56                                                                                                        inoperable: ab,ti                                                                                                           12,989
                       \#57                                                                                                       in\* operable: ab,ti                                                                                                         13,465
                       \#58                                                                                                       unresectable: ab,ti                                                                                                          15,735
                       \#59                                                                                                     non\* resectable: ab,ti                                                                                                        1,208
                       \#60                                                                                                       late\* stage: ab,ti                                                                                                            84
                       \#61                                                                                                   late: ab,ti AND stage: ab,ti                                                                                                     41,346
                       \#62                                                                                               metast\*: ab,ti OR advance\*: ab,ti                                                                                                 900,959
                       \#63                                          relaps\* OR recurr\* OR unresect\* OR non?resect\* OR in?operable OR non?operable OR un?operable OR advanc\* OR metasta\* OR late NEAR/2 stage                                          1,895,338
                       \#64                                                                                                           \#34 OR \#35                                                                                                             61,621
                       \#65   \#36 OR \#37 OR \#38 OR \#39 OR \#40 OR \#41 OR \#42 OR \#43 OR \#44 OR \#45 OR \#46 OR \#47 OR \#48 OR \#49 OR \#50 OR \#51 OR \#52 OR \#53 OR \#54 OR \#55 OR \#56 OR \#57 OR \#58 OR \#59 OR \#60 OR \#61 OR \#62 OR \#63   1,943,775
                       \#66                                                                                                          \#64 AND \#65                                                                                                             33,907
                       \#67                                                                                                          \#33 AND \#66                                                                                                             2,689
   Language and year   \#68                                                                                              \[1995--2013\]/py AND \[english\]/lim                                                                                               12,998,680
         Final         \#69                                                                                                          \#67 AND \#68                                                                                                             2,901

###### 

Ovid/MEDLINE search strategy

   **Ovid/MEDLINE search**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ------------------------- ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------
        Design terms         \#1                                                                                                                                                                                                                                      Randomized Controlled Trials as Topic/                                                                                                                                                                                                                                      100,690
                             \#2                                                                                                                                                                                                                                           Randomized Controlled Trial/                                                                                                                                                                                                                                           382,290
                             \#3                                                                                                                                                                                                                                                Random Allocation/                                                                                                                                                                                                                                                80,788
                             \#4                                                                                                                                                                                                                                               Double Blind Method/                                                                                                                                                                                                                                               129,303
                             \#5                                                                                                                                                                                                                                          controlled clinical trial.pt.                                                                                                                                                                                                                                           88,866
                             \#6                                                                                                                                                                                                                                         randomized controlled trial.pt.                                                                                                                                                                                                                                          382,290
                             \#7                                                                                                                                                                                                                                                 Clinical Trial/                                                                                                                                                                                                                                                  499,767
                             \#8                                                                                                                                                                                                                                                clinical trial.pt.                                                                                                                                                                                                                                                499,767
                             \#9                                                                                                                                                                                                                                            Clinical Trials as Topic/                                                                                                                                                                                                                                             173,590
                             \#10                                                                                                                                                                                                                                           1 or 2 or 3 or 4 or 5 or 6                                                                                                                                                                                                                                            631,570
                             \#11                                                                                                                                                                                                                                                  7 or 8 or 9                                                                                                                                                                                                                                                    602,541
                             \#12                                                                                                                                                                                                                   ((singl\* or doubl\* or treb\* or tripl\*) and (blind\* or mask\*)).ab,ti.                                                                                                                                                                                                                    145,496
                             \#13                                                                                                                                                                                                                                                   Placebos/                                                                                                                                                                                                                                                     33,372
                             \#14                                                                                       ((random\* and (clinical or control\*) and trial) or (placebo\* and (\"randomly allocated\" or (allocated and random\*)))).mp. \[mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier\]                                                                                        457,488
                             \#15                                                                                                                                                                                                                                                 12 or 13 or 14                                                                                                                                                                                                                                                  513,100
                             \#16                                                                                                                                                                                                                                                   11 and 15                                                                                                                                                                                                                                                     264,991
                             \#17                                                                                                                                                                                                                                                    10 or 16                                                                                                                                                                                                                                                     645,804
        Disease terms        \#18                                                                                                                                                                                                    ((lung\* or pulmon\*) and (adenocarcinom\* or squamous or \"large cell\" or \"non-small cell\")).ab,ti.                                                                                                                                                                                                      59,093
                             \#19                                                                                                                                                                                                                                        Carcinoma, Non-Small-Cell Lung/                                                                                                                                                                                                                                          34,861
                             \#20   (metastatic or advanced or stage or \"stage 3\" or stage4 or \"stage 4\" or stageIII or \"stage III\" or StageIV or \"Stage IV\" or Stage?III or \"Stage ?III\" or Stage?IV or \"Stage ?IV\" or \"StageIII/IV\" or \"Stage III/IV\" or \"StageIII?/IV?\" or \"Stage III?/IV?\" or \"StageIII/StageIV\" or \"Stage III/Stage IV\" or \"StageIII?/StageIV?\" or \"Stage III?/Stage IV?\" or inoperable or in?operable or unresectable or non?resectable or \"late?stage\" or (metast\* or advance\*)).ab,ti.   1,177,250
                             \#21                                                                                                                                                                                                                                                    18 or 19                                                                                                                                                                                                                                                     66,533
                             \#22                                                                                                                                                                                                                                                   20 and 21                                                                                                                                                                                                                                                     34,403
                             \#23                                                                                                                                                                                                                                                   17 and 22                                                                                                                                                                                                                                                      3,600
       Exclusion terms       \#24                                                                                                                                                                                                                                               case report.ab,ti.                                                                                                                                                                                                                                                201,610
                             \#25                                                                                                                                                                                                                                                   review.pt.                                                                                                                                                                                                                                                   1,893,388
                             \#26                                                                                                                                                                                                                                                   letter.pt.                                                                                                                                                                                                                                                    817,960
                             \#27                                                                                                                                                                                                                                          Clinical Trial, Phase I.pt.                                                                                                                                                                                                                                            15,867
                             \#28                                                                                                                                                                                                                                              Historical Article/                                                                                                                                                                                                                                                298,058
                             \#29                                                                                                                                                                                                                                            systematic review.ab,ti.                                                                                                                                                                                                                                             44,587
                             \#30                                                                                                                                                                                                                                             clinical review.ab,ti.                                                                                                                                                                                                                                               3,354
                             \#31                                                                                                                                                                                                                                     24 or 25 or 26 or 27 or 28 or 29 or 30                                                                                                                                                                                                                                     3,184,956
                             \#32                                                                                                                                                                                                                                                   23 not 31                                                                                                                                                                                                                                                      2,702
          Rx terms           \#33                                                                                                                                                                                  drug therapy/ or treatment outcome/ or (\"treatment\" and \"response\").ab,ti. or (\"drug\" and \"efficacy\").ab,ti. or outcome assessment/                                                                                                                                                                                   1,014,086
                             \#34                                                                                                                                                                                                                                                   32 and 33                                                                                                                                                                                                                                                      1,611
            Final            \#35                                                                                                                                                                                                                                       limit 34 to yr = \"1995 -Current\"                                                                                                                                                                                                                                         1,464

The following is a list of the conference databases that will be searched:

• American Association for Cancer Research, AACR

• American College of Radiation Oncology

• American Society for Radiation Oncology, ASTRO

• American Society of Clinical Oncology, ASCO

• Asia Pacific Lung Cancer Conference, APLCC

• Asia Pacific Oncology Summit, APOS

• Asian Oncology Summit, AOS

• Atualizacoes em Oncologia

• Australian Lung Cancer Conference, ALCC

• Austrian Society of Haematology and Oncology, ASHO

• The Association for Cancer Surgery, BASO

• Biennial Congress of the European Association for Cancer Research, EACR

• British Thoracic Oncology Group Conference, BTOG

• Clinical Oncology Society of Australia, COSA

• Cancer Symposium of the Society of Surgical Oncology, CSSSO

• Chicago Supportive Oncology Conference, CSOC

• Clinical Interventional Oncology, CIO

• Congres National de la Societe Francaise de Radiotherapie Oncologique, SFRO

• Congress of the European Society for Medical Oncology, ESMO

• Congress of the European Society of Surgical Oncology, ESSO

• Congress of the International Society of Oncology and Biomarkers, ISOBM

• Educational Cancer Convention Lugano of the European School of Oncology, ECCLU

• European Lung Cancer Conference, ELCC

• European Multidisciplinary Cancer Congress

• European Multidisciplinary Conference in Thoracic Oncology, EMCTO

• Hematology Oncology Pharmacy Association Annual Meeting, HOPA

• International Conference and Exhibition on Cancer Science and Therapy, IMPAKT

• International Conference of the Society for Integrative Oncology

• International Lung Cancer Congress

• International Symposium on Targeted Anticancer Therapies, TAT

• Italian Society of Surgical Oncology Conference

• Medical Oncology Group of Australia, MOGA

• Oncology Platform and Poster Presentation, CSM 2009

• Scientific Association of Swiss Radiation Oncology, SASRO

• Scientific Meeting of the International Society for Biological Therapy of Cancer

• Scientific Meeting of the Society for Immunotherapy of Cancer, SITC

• Symposium of the International Society of Oncology Pharmacy Practitioners

• UK Radiation Oncology Conference

• World Conference on Interventional Oncology, WCIO

• World Congress on Cancer Science and Therapy

Eligibility assessment
----------------------

To be eligible, published studies must meet the criteria outlined in Table  [4](#T4){ref-type="table"}. Briefly, eligible articles must report at least one of the following outcomes (overall survival, progression-free survival, quality of life, or toxicity) for patients with squamous NSCLC. Eligible articles must report data from randomized controlled trials published since 1995. Abstracts of all potentially eligible citations will be reviewed and excluded if it can be definitively stated that no eligibility criterion is met. All other publications will be considered potentially eligible. Full-text articles of all potentially eligible citations will be obtained and reviewed to determine final eligibility. The eligibility of both the abstracts and full-text articles will be assessed independently by two reviewers using the criteria and screening matrix presented in Table  [4](#T4){ref-type="table"}. If the two reviewers do not agree on the eligibility of an article, a third reviewer will serve as the tie breaker. Systematic reviews and other review articles will be scanned to ensure no eligible randomized controlled trials (RCTs) are missed.

###### 

Eligibility criteria and screening matrix

                 **Eligibility criteria**                                                                                                                                                                                                               
  ------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------- -------------------------------------------------------------------------------
                         Patients                        Male or female patients with histologically or cytologicallyconfirmed squamous NSCLC                                                                                                           
                                                         Study participants must have not received chemotherapy treatment prior to first-line chemotherapy for NSCLC at the time of randomization in the study                                          
                      Interventions                      The study assesses a chemotherapy treatment in each of the study arms                                                                                                                          
                                                         No limits are placed on the type of chemotherapy used                                                                                                                                          
                         Outcomes                        One or more of the following outcomes must be quantitatively reported in the publication: overall survival, progression-free survival, toxicity, or quality of life                            
                                                         At least one of the required outcome variables must be reported separately for patients with advanced or metastatic (stage III/IV) NSCLC that is of squamous histology                         
                       Study design                      RCTs                                                                                                                                                                                           
                        Time frame                       1995 to present                                                                                                                                                                                
                **Ineligibility criteria**                                                                                                                                                                                                              
                      Interventions                      Not first-line treatment with first-line defined as patients with no prior exposure to chemotherapy                                                                                            
                                                         Radiation therapy in the absence of concurrent chemotherapy in any treatment group                                                                                                             
                       Study design                      Review articles, news, editorials, commentaries                                                                                                                                                
                        Time frame                       Publication date prior to 1995                                                                                                                                                                 
   **Matrix for patients with \"squamous histology\"**                                                                                                                                                                                                  
       **Squamous inclusion obvious in abstract?**       **Squamous results obvious in abstract?**                                                                                                                                **Inclusion**         **Comments**
                           Yes                           Yes                                                                                                                                                                      Yes                    
                            No                           Yes                                                                                                                                                                      Yes                    
                           Yes                           No                                                                                                                                                                       Yes/No                Need full text to determine the inclusion
                            No                           No                                                                                                                                                                       Yes/No                Need full text to determine the inclusion
   **Only non-squamous inclusion obvious in abstract?**  **Squamous results obvious in abstract?**                                                                                                                                **Inclusion**         **Comments**
                           Yes                           Yes                                                                                                                                                                      Not possible case      
                            No                           Yes                                                                                                                                                                      Yes                    
                           Yes                           No                                                                                                                                                                       No                     
                            No                           No                                                                                                                                                                       Yes/No                Need full text to determine the inclusion
      **Abstract mentions just NSCLC as inclusion?**     **Squamous results obvious in abstract?**                                                                                                                                **Inclusion**         **Comments**
                           Yes                           Yes                                                                                                                                                                      Yes                    
                            No                           Yes                                                                                                                                                                      Yes/No                This may be multisite cancer study, need full text to determine the inclusion
                           Yes                           No                                                                                                                                                                       Yes/No                Need full text to determine the inclusion
                            No                           No                                                                                                                                                                       Noise in the search   Need full text to determine the inclusion
                     Multiple cancers                    If mentions lung cancer                                                                                                                                                  Yes/No                Need full text to determine the inclusion
                                                         If does not mention any specific tumor types                                                                                                                             Yes/No                Need full text to determine the inclusion
                                                         If only mentions breast cancer or other types and does not mention lung cancer                                                                                           Noise in the search    
       **Matrix for \"not first-line treatment\"**                                                                                                                                                                                                      
                      **Condition**                      **Line of treatment to be considered**                                                                                                                                   **Inclusion**         **Comments**
                   Naïve NSCLC patients                  1st                                                                                                                                                                      Yes                    
              First- or front-line treatment             1st                                                                                                                                                                      Yes                    
                 Untreated NSCLC patients                1st                                                                                                                                                                      Yes                    
          Metastatic chemo-naïve NSCLC patients          1st                                                                                                                                                                      Yes                    
                Chemo-naïve NSCLC patients               1st                                                                                                                                                                      Yes                    
                  Second-line treatment                  2nd                                                                                                                                                                      No                     
              (Rx)-resistant NSCLC patients              2nd                                                                                                                                                                      No                     
             Recurrent or progressive disease            2nd                                                                                                                                                                      No                     
          (Rx)-responder/non-responder patients          2nd                                                                                                                                                                      No                     
       If no clear information on line of treatment      NA                                                                                                                                                                       Yes/No                Need full text to determine the inclusion

Data extraction and verification
--------------------------------

In a process similar to that used for assessing eligibility, two reviewers will independently extract the data elements listed in Table  [5](#T5){ref-type="table"} from each eligible article. These data are extensive and it is not expected, nor is it required, that all studies will report all data fields included. However, attempts to collect as extensive of data as possible will be made to increase the potential range of sensitivity and descriptive analyses. In addition to the data extraction, two reviewers will also assess bias using the Cochrane Risk of Bias Tool and will measure study quality using the Physiotherapy Evidence Database (PEDro) scale (see the \"Assessment of bias and study quality\" section). Data from both reviewers will be compared. If any data element does not match, the reviewers will meet and attempt to resolve the discrepancies. In cases of non-resolution, a third reviewer will be consulted. All rules and decision criteria used in the data resolution process will be recorded for quality assurance and methodological consistency purposes. To further ensure the accuracy of the extracted data, a subset of 10% of all extracted articles will be verified by an individual not involved in the data extraction process. In cases of error detection, the full database will be reviewed to ensure accuracy.

###### 

Variables for data extraction

  **Arm-phase-period information by study arm and overall**                                                                                                                                                                                                                                                                                                                                                                                    
  ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Arm                                                                                                               Unique arm number. Unique number for the treatment arm is a grouping variable that is used to highlight which outcome is in the same group of subjects                                                                                                                                                                     Integer, in case of sub-analysis arm use A.a format. Placebo = 0, for sub-arm 0.1
  Number of study arms                                                                                                                                                                                                                                                                                                                                                                                                                         1, 2, 3
  Open label versus blinded                                                                                                                                                                                                                                                                                                                                                                                                                     
  Phase of study                                                                                                                                                                                                                                                                                                                                                                                                                               1, 2, 3, or unknown
  Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                   OS, PFS, RR, TPD, etc.
  Patients randomized                                                                                               Number of patients randomized to the arm                                                                                                                                                                                                                                                                                   Number value
  Arm description                                                                                                   Description of the treatment arm usually includes the drug name, dose, and frequency                                                                                                                                                                                                                                       e.g., methotrexate 10 mg QW (once a week)
  Sub arm analysis                                                                                                  Indicates if the analysis is in a subset of study arm                                                                                                                                                                                                                                                                      Yes, NA. Use all in case of AE or dropout data is reported for the randomized trial population
  Arm comment                                                                                                       Comment referring to the arm                                                                                                                                                                                                                                                                                               Comment in relevance to the understating of arm or NA
  Study phase                                                                                                       Description of the specific phase within the overall study from which the data is derived                                                                                                                                                                                                                                  Lead-in, active, follow-up
  Study phase description                                                                                           Qualifies the \"Study Phase\" field with any additional information deemed necessary or helpful for that arm                                                                                                                                                                                                               e.g., open-label follow-up
  Phase duration                                                                                                    Length of time of the study phase from which the data is derived for the arm                                                                                                                                                                                                                                               Time
  Phase duration unit                                                                                               Time unit for phase duration for the arm                                                                                                                                                                                                                                                                                   Units
  Phase comment                                                                                                     Comment concerning the study phase                                                                                                                                                                                                                                                                                         Any comment that is relevant to the understanding of the phase or NA
  Period                                                                                                            Used if necessary to separate crossover periods within a crossover trial                                                                                                                                                                                                                                                   If the phase has multiple periods, the number of the period. Integer in sequence, or NA
  Period description                                                                                                Used to qualify the \"Period\" field with any additional information deemed necessary or helpful                                                                                                                                                                                                                           e.g., treatment A, titration, maintenance, NA
  Period duration                                                                                                   Length of time of the period in a study phase from which the data is derived                                                                                                                                                                                                                                               Time, NA
  Period duration unit                                                                                              Time unit for period duration                                                                                                                                                                                                                                                                                              Units, NA
  Period comment                                                                                                    Comment concerning the period                                                                                                                                                                                                                                                                                              Any comment that is relevant to the understanding of the period or NA
  Repository                                                                                                        Description                                                                                                                                                                                                                                                                                                                Data entry standards
  **Demographics and medical history information at baseline by study arm and overall---adjusted and unadjusted**                                                                                                                                                                                                                                                                                                                              
  Age                                                                                                               Mean (or median) age in years of patient population or treatment arm population                                                                                                                                                                                                                                            Age in years or NR if not mentioned specifically or clearly in the trial
  Percent female                                                                                                    Percent of females in the patient population or treatment arm population                                                                                                                                                                                                                                                   Percent or NR if not mentioned specifically or clearly in the trial
  Weight                                                                                                            Mean body weight of the patient or treatment arm population                                                                                                                                                                                                                                                                Weight in kg, normalize if needed or NR if not mentioned specifically or clearly in the trial
  Height                                                                                                            Mean height of the patient or treatment arm population                                                                                                                                                                                                                                                                     Height in cm, normalize if needed or NR if not reported
  BMI                                                                                                               Mean body mass index of the treatment arm population                                                                                                                                                                                                                                                                       BMI in kg/m^2^, normalize if needed or NR if not reported in the trial
  DBP                                                                                                               Mean (or median) diastolic blood pressure                                                                                                                                                                                                                                                                                  mmHg
  SBP                                                                                                               Mean (or median) systolic blood pressure                                                                                                                                                                                                                                                                                   mmHg
  Inclusion                                                                                                         Description of treatment arm or sub-arm inclusion criteria under the trial protocol                                                                                                                                                                                                                                        e.g., for sub-group females only, or NR if not mentioned specifically or clearly in the trial
  Exclusion                                                                                                         Description of treatment arm or sub-arm exclusion criteria under the trial protocol                                                                                                                                                                                                                                        e.g., for sub-group exclusion of females with child-bearing potential, or NR if not mentioned specifically or clearly in the trial
  Ethnic white                                                                                                      Percent of the ethnic population who are whites or Caucasian in the trial                                                                                                                                                                                                                                                  Percent or NR if not mentioned specifically or clearly in the trial
  Ethnic black                                                                                                      Percent of the ethnic population who are black in the trial                                                                                                                                                                                                                                                                Percent or NR if not mentioned specifically or clearly in the trial
  Ethnic Hispanic                                                                                                   Percent of the ethnic population who are Hispanic in the trial                                                                                                                                                                                                                                                             Percent or NR if not mentioned specifically or clearly in the trial
  Ethnic Asian                                                                                                      Percent of the ethnic population who are Asian in the trial                                                                                                                                                                                                                                                                Percent or NR if not mentioned specifically or clearly in the trial
  Ethnic other                                                                                                      Percent of the ethnic population who are other in the trial                                                                                                                                                                                                                                                                Percent or NR if not mentioned specifically or clearly in the trial
  Primary disease                                                                                                   Primary disease being studied                                                                                                                                                                                                                                                                                               
  Percent current smokers                                                                                           Percent of the population who are current smokers                                                                                                                                                                                                                                                                          Percent or NR if not mentioned specifically or clearly in the trial
  Percent previous smokers                                                                                          Percent of the population who are previous smokers                                                                                                                                                                                                                                                                         Percent or NR if not mentioned specifically or clearly in the trial
  Percent adenocarcinoma type                                                                                       Percent subjects with NSCLC adenocarcinoma type                                                                                                                                                                                                                                                                            Percent or NR if not mentioned specifically or clearly in the trial
  Percent squamous cell carcinoma type                                                                              Percent subjects with NSCLC squamous cell carcinoma type                                                                                                                                                                                                                                                                   Percent or NR if not mentioned specifically or clearly in the trial
  Percent non-squamous                                                                                                                                                                                                                                                                                                                                                                                                                          
  Percent NSCLC stage 0**/**I**/**II                                                                                Percent subjects with NSCLC stage 0 or I or II                                                                                                                                                                                                                                                                             Percent or NR if not mentioned specifically or clearly in the trial
  Percent NSCLC stage III                                                                                           Percent subjects with NSCLC stage III                                                                                                                                                                                                                                                                                      Percent or NR if not mentioned specifically or clearly in the trial
  Percent NSCLC stage IV                                                                                            Percent subjects with NSCLC stage IV                                                                                                                                                                                                                                                                                       Percent or NR if not mentioned specifically or clearly in the trial
  Percent NSCLC stage III/IV total                                                                                  Total percent of subjects with NSCLC stages III or IV                                                                                                                                                                                                                                                                      Percent or NR if not mentioned specifically or clearly in the trial
  Percent ECOG status 0                                                                                             Percent subjects with Eastern Cooperative Oncology Group performance status scale 0                                                                                                                                                                                                                                        Percent or NR if not mentioned specifically or clearly in the trial
  Percent ECOG status 1                                                                                             Percent subjects with Eastern Cooperative Oncology Group performance status scale 1                                                                                                                                                                                                                                        Percent or NR if not mentioned specifically or clearly in the trial
  Percent ECOG status 0/1 total                                                                                     Percent subjects with Eastern Cooperative Oncology Group performance status scales 0 or 1                                                                                                                                                                                                                                  Percent or NR if not mentioned specifically or clearly in the trial
  Percent Karnofsky status ≥80                                                                                      Percent subjects with Karnofsky's index of performance status \>80%                                                                                                                                                                                                                                                        Percent or NR if not mentioned specifically or clearly in the trial
  Percent WHO performance status 0/1                                                                                Percent subjects with WHO performance status scale 0 or 1                                                                                                                                                                                                                                                                  Percent or NR if not mentioned specifically or clearly in the trial
  Num of metastatic lymph nodes                                                                                     Mean or median number of metastatic lymph nodes                                                                                                                                                                                                                                                                            NR if not mentioned specifically or clearly in the trial
  Percent metastatic L-node positive                                                                                Percent subjects who are lymph node positive or with metastatic lymph nodes                                                                                                                                                                                                                                                Percent or NR if not mentioned specifically or clearly in the trial
  Percent bone metastasis                                                                                           Percent subjects with bone metastasis                                                                                                                                                                                                                                                                                      Percent or NR if not mentioned specifically or clearly in the trial
  Percent brain metastasis                                                                                          Percent subjects with brain metastasis                                                                                                                                                                                                                                                                                     Percent or NR if not mentioned specifically or clearly in the trial
  Percent liver metastasis                                                                                          Percent subjects with lung metastasis                                                                                                                                                                                                                                                                                      Percent or NR if not mentioned specifically or clearly in the trial
  Percent other metastasis                                                                                          Percent subjects with other metastatic organs                                                                                                                                                                                                                                                                              Percent or NR if not mentioned specifically or clearly in the trial
  Percent metastatic organ sites 1                                                                                  Percent subjects with one metastatic organ or site involved                                                                                                                                                                                                                                                                Percent or NR if not mentioned specifically or clearly in the trial
  Percent metastatic organ sites 2                                                                                  Percent subjects with two metastatic organs or sites involved                                                                                                                                                                                                                                                              Percent or NR if not mentioned specifically or clearly in the trial
  Percent metastatic organ sites \>3                                                                                Percent subjects with three or more metastatic organs or sites involved                                                                                                                                                                                                                                                    Percent or NR if not mentioned specifically or clearly in the trial
  Percent hemoglobin \<11.5 g/dl                                                                                    Percent subjects with baseline hemoglobin levels \<11.5 g/dl                                                                                                                                                                                                                                                               Percent or NR if not mentioned specifically or clearly in the trial
  Patient demographic comments                                                                                      Any pertinent demographic comments that are not dealt by other variables                                                                                                                                                                                                                                                   Any comment that may be relevant to the understanding of the demographic characteristics of the patient population
  Percent previous surgery                                                                                          Subjects with previous treatment for NSCLC as complete or partial surgery. Procedures include wedge resection (removal of part of a lobe), segmentectomy (removal of an anatomic division of a particular lobe of the lung), lobectomy (one lobe), bilobectomy (two lobes), or pneumonectomy (whole lung)                  Percent or NR if not mentioned specifically or clearly in the trial
  Percent previous radiotherapy                                                                                     Percent subjects with previous radiotherapy as treatment for NSCLC                                                                                                                                                                                                                                                         Percent or NR if not mentioned specifically or clearly in the trial
  Percent previous chemotherapy                                                                                     Percent subjects with previous chemotherapy as treatment for NSCLC                                                                                                                                                                                                                                                         Percent or NR if not mentioned specifically or clearly in the trial
  Comorbidities                                                                                                                                                                                                                                                                                                                                                                                                                                At baseline and by treatment arm
  Percent comorbidities                                                                                                                                                                                                                                                                                                                                                                                                                        At baseline and by treatment arm;% or NR
  Percent previous platinum                                                                                                                                                                                                                                                                                                                                                                                                                     
  Percent no previous treatment                                                                                     Percent subjects with no treatment for NSCLC                                                                                                                                                                                                                                                                               Percent or NR if not mentioned specifically or clearly in the trial
  Previous treatment comments                                                                                       Comments regarding the previous treatment                                                                                                                                                                                                                                                                                  Any comment that may be relevant to the understanding of the previous NSCLC treatment in this record, NA if no comments
  **Pharmacological therapy information**                                                                                                                                                                                                                                                                                                                                                                                                      
  **Repository**                                                                                                    **Description**                                                                                                                                                                                                                                                                                                            **Data entry standards**
  Primary NSCLC therapy                                                                                             Name of primary drug therapy used in this arm at that time point                                                                                                                                                                                                                                                           NSCLC drug, e.g., cisplatin, docetaxel
  Primary NSCLC dose                                                                                                Randomized daily dose at time of outcome. Please note that this is the dose the patients were receiving when the observation is made (not the first randomized dose). If the treatment is switched at the time of observation, record the prior treatment the patients were getting just before the observation was made   Total daily dose at the time of observation
  Primary NSCLC dose achieved                                                                                       Average daily dose during assessment period or for the total treatment period                                                                                                                                                                                                                                              Average daily dose achieved. Specifically useful for dose titration and crossover trials, NA for the fixed dose trials as both dose achieved and total daily dose do not vary
  Primary NSCLC dose unit                                                                                           Unit of total daily or average dose achieved                                                                                                                                                                                                                                                                               Unit, NR if not reported
  Primary NSCLC dose freq/cycle                                                                                                                                                                                                                                                                                                                                                                                                                 
  Primary Rx days of administration                                                                                                                                                                                                                                                                                                                                                                                                            e.g., d1, d8
  Primary therapy duration and route of administration                                                                                                                                                                                                                                                                                                                                                                                         e.g., 10 min i.v. infusion
  Primary NSCLC Rx cycle duration                                                                                                                                                                                                                                                                                                                                                                                                               
  Primary NSCLC Rx number of cycles                                                                                                                                                                                                                                                                                                                                                                                                             
  Primary NSCLC formulation                                                                                         Special treatment formulation                                                                                                                                                                                                                                                                                              Only specialized formulations like IR, CR, SR
  Primary NSCLC therapy status                                                                                      Indicates whether the observation refers to the first, continuing or last dose of the therapy                                                                                                                                                                                                                              Start = first dose starts on at this time, continuing = treatment is continuing at this time, end = treatment has been discontinued at this time (last dose)
  Primary NSCLC dose comments                                                                                       Comment regarding the dosing of primary NSCLC treatment                                                                                                                                                                                                                                                                    Any comment that may be relevant to the understanding the dosing of the primary treatment in this record, NA if no comments
  Combo NSCLC therapy                                                                                               Name of secondary NSCLC therapy used in this arm in addition to the primary treatment at that time point                                                                                                                                                                                                                   NSCLC drug, e.g., PTH NA if no secondary NSCLC therapy
  Combo NSCLC dose                                                                                                  Randomized daily dose of the secondary NSCLC therapy at time of outcome. Refer to the dose description of primary NSCLC dose                                                                                                                                                                                               Total daily dose at the time of observation, NR if not reported and NA if no secondary NSCLC therapy
  Combination NSCLC dose achieved                                                                                   Average daily dose of the secondary NSCLC therapy during assessment period or for the total treatment period                                                                                                                                                                                                               Average daily dose achieved. Specifically useful for dose titration and crossover trials, NA for the fixed dose trials as both dose achieved and total daily dose do not vary
  Combination NSCLC dose unit                                                                                       Unit of total daily or average dose achieved for the secondary NSCLC therapy                                                                                                                                                                                                                                               Unit, NR if not reported or NA if no secondary NSCLC therapy
  Combination NSCLC dose reg                                                                                        Frequency of secondary NSCLC therapy being administered                                                                                                                                                                                                                                                                    QD, BID, etc., NA if no secondary NSCLC therapy
  Combination NSCLC dose freq/cycle                                                                                                                                                                                                                                                                                                                                                                                                             
  Combination Rx days of administration                                                                                                                                                                                                                                                                                                                                                                                                        e.g., d1, d8
  Combination Rx duration and route of administration                                                                                                                                                                                                                                                                                                                                                                                          e.g., 10 min i.v. infusion
  Combination NSCLC Rx cycle duration                                                                                                                                                                                                                                                                                                                                                                                                           
  Combination NSCLC Rx number of cycles                                                                                                                                                                                                                                                                                                                                                                                                         
  Combination NSCLC dose comment                                                                                    Comment regarding the dosing of secondary NSCLC therapy                                                                                                                                                                                                                                                                    Any comment that may be relevant to the understanding the dosing of the secondary treatment in this record, NA if no comments or no secondary NSCLC therapy
  Concomitant medications                                                                                                                                                                                                                                                                                                                                                                                                                      Baseline or by treatment arm
  **Radiation therapy information**                                                                                                                                                                                                                                                                                                                                                                                                            
  **Repository**                                                                                                    **Description**                                                                                                                                                                                                                                                                                                            **Data entry standards**
  Radiation therapy type                                                                                                                                                                                                                                                                                                                                                                                                                        
  Radiation therapy comments                                                                                                                                                                                                                                                                                                                                                                                                                    
  **Assessment characterization**                                                                                                                                                                                                                                                                                                                                                                                                              
  **Repository**                                                                                                    **Description**                                                                                                                                                                                                                                                                                                            **Data entry standards**
  Assessment                                                                                                        Common name for assessment that this record refers to, e.g., PANSS                                                                                                                                                                                                                                                         As in the assessments and conventions sheet
  Assessment short form                                                                                             Code for the assessment                                                                                                                                                                                                                                                                                                    As in the assessments and conventions sheet
  Assessment comment                                                                                                Any comment that describes the nature of the assessment                                                                                                                                                                                                                                                                    e.g., plasma glucose level, NA if no comments
  Assessment location                                                                                               Location from where the assessment value is taken or extracted from the manuscript                                                                                                                                                                                                                                         Table number, figure number, page number
  Assessment category                                                                                               Describes what the assessment value represented is, whether it is absolute, change from baseline (CFB), percent change from baseline (PCFB), or fraction of randomized patients with the event, count in case of tender or swollen joint counts                                                                            Absolute, CFB, PCFB, Frac, or Count
  Assessment Stat parameter                                                                                         The summary parameter of the assessment value                                                                                                                                                                                                                                                                              Mean, median, percent, NR if not reported
  Stat population                                                                                                   Statistical population for which the efficacy/safety analyses were done and value reported                                                                                                                                                                                                                                 ITT, OC, completers, randomized, PPP (per protocol population: define), NR if not reported
  Missing data treatment                                                                                            Method used for handling with missing observations in computing the summary parameter                                                                                                                                                                                                                                      LOCF (last observation carried forward), none, NR if not reported and NA in case of completers
  Scale lower limit                                                                                                 Scale lower limit                                                                                                                                                                                                                                                                                                          The lower limit of the scale for the assessment, NA if not applicable
  Scale upper limit                                                                                                 Scale upper limit                                                                                                                                                                                                                                                                                                          The upper limit of the scale for the assessment, NA if not applicable
  Assessment categories or words                                                                                    Scale category description                                                                                                                                                                                                                                                                                                 Category that is associated with each point of the scale
  Total levels                                                                                                      Total categories/points in the scale                                                                                                                                                                                                                                                                                       The total number of categories associated with each point of the scale, e.g., 0 to 4 point scale
  Total symptoms                                                                                                    Total symptoms in the scale                                                                                                                                                                                                                                                                                                The total number of symptoms associated with the respective assessment, NA if not applicable
  Total score lower limit                                                                                           Lower limit of the scale, this is calculated as the number of levels multiplied with the lowest possible scale                                                                                                                                                                                                             Integer value, NA if not applicable
  Total score upper limit                                                                                           Upper limit of the scale, this is calculated as the number of levels multiplied with the highest possible scale                                                                                                                                                                                                            Integer value, NA if not applicable
  Assessment level                                                                                                  For ordered categorical data \"scales.\" Indicates which level in the categorical scale the assessment is referring to                                                                                                                                                                                                     Integer level from 1 to number of levels, if fractional responder type, enter responder threshold value, eg., ≥5% weight loss from baseline for total body weight assessment, etc., NA if not applicable
  PROs                                                                                                              Scale, mean value, SD by group, time point                                                                                                                                                                                                                                                                                  
  **Time, assessment, and baseline value information**                                                                                                                                                                                                                                                                                                                                                                                         
  **Repository**                                                                                                    **Description**                                                                                                                                                                                                                                                                                                            **Data entry standards**
  Assessment visit                                                                                                  Clinical visit at which the assessment is done                                                                                                                                                                                                                                                                             Visit 1 (usually baseline) is the first visit in the active phase. Lead in visits start at -1 and count backwards, NR if not reported
  Assessment time reported                                                                                          Time at which the assessment is done during the study and as reported in the manuscript                                                                                                                                                                                                                                    Visit 1 = baseline = time 0 and the lead in assessment time starts at -1 and count backwards
  Assessment time unit reported                                                                                     Unit for reported assessment time                                                                                                                                                                                                                                                                                          Time unit as reported
  Assessment time range reported                                                                                    In case if the assessment values are average over a time interval                                                                                                                                                                                                                                                          e.g., weeks 2 through 28 enter 2--28
  Assessment time normalized                                                                                        Normalized time in days at which the assessment is done during the study and as reported in the manuscript                                                                                                                                                                                                                 The normalized time value using the normalized unit as days, e.g., 4 weeks = 28 days
  Assessment time unit normalized                                                                                   Unit for standard assessment time                                                                                                                                                                                                                                                                                          Days is the standard unit
  Assessment value                                                                                                  Assessment value reported at that time point                                                                                                                                                                                                                                                                               Assessment value as reported
  Assessment unit                                                                                                   Assessment unit as reported                                                                                                                                                                                                                                                                                                Assessment unit as reported, NA if not applicable
  Assessment SE                                                                                                     SE of reported assessment value                                                                                                                                                                                                                                                                                            SE as reported, NR if not reported
  Assessment SD                                                                                                     SD of reported assessment value                                                                                                                                                                                                                                                                                            SD as reported, NR if not reported
  Assessment CI type                                                                                                                                                                                                                                                                                                                                                                                                                            
  Assessment lower CI                                                                                                                                                                                                                                                                                                                                                                                                                           
  Assessment upper CI                                                                                                                                                                                                                                                                                                                                                                                                                           
  Assessment value normalized                                                                                       Assessment value converted into normalized assessment units                                                                                                                                                                                                                                                                Still insert value here, report if normalized units are the same as the reported units
  Assessment value unit norm                                                                                        Normalized assessment value units                                                                                                                                                                                                                                                                                          See assessments and conventions sheet for normalized assessment standard
  Assessment SE normalized                                                                                          Standard error of normalized assessment value                                                                                                                                                                                                                                                                              SE in the same units as normalized assessment, may need to be calculated from SD and *N*; if not provided, NA
  Assessment SD normalized                                                                                          Standard deviation of normalized assessment value                                                                                                                                                                                                                                                                          SD in the same units as normalized assessment, may need to be calculated from SE and *N*; if not provided, NA
  Assessment CI type normalized                                                                                                                                                                                                                                                                                                                                                                                                                 
  Assessment lower CI normalized                                                                                                                                                                                                                                                                                                                                                                                                                
  Assessment upper CI normalized                                                                                                                                                                                                                                                                                                                                                                                                                
  Assessment number                                                                                                 Number of patients assessed at that time point and the value derived                                                                                                                                                                                                                                                       Integer value, but for responders and dropouts, this value is calculated from the percentages reported in the trial
  Assessment value comment                                                                                          Comment pertaining to the assessment value that cannot be dealt by other variables                                                                                                                                                                                                                                         e.g., the assessment value is the mean of last 7 days of before each clinical visit, etc.
  Hazard ratio                                                                                                      95% confidence intervals, progression-free survival, and overall survival---adjusted and unadjusted                                                                                                                                                                                                                         
  Baseline visit                                                                                                    Clinical visit at which the baseline assessment is done                                                                                                                                                                                                                                                                    Visit 1 = baseline = time 0, NR if not reported
  Baseline time                                                                                                     Time at which the baseline assessment is done                                                                                                                                                                                                                                                                              Visit 1 = baseline = time 0
  Baseline time unit                                                                                                Unit for reported baseline time                                                                                                                                                                                                                                                                                            Time unit as reported
  Baseline time normalized                                                                                          Normalized time in days at which the baseline is done during the study and as reported in the manuscript                                                                                                                                                                                                                   The normalized time value using the normalized unit as days, e.g., -4 weeks = -28 days
  Baseline time unit normalized                                                                                     Unit for standard baseline time                                                                                                                                                                                                                                                                                            Days is the standard unit
  Baseline value                                                                                                    Absolute baseline value for that assessment                                                                                                                                                                                                                                                                                Absolute baseline value
  Baseline value unit                                                                                               Assessment unit as reported                                                                                                                                                                                                                                                                                                Assessment unit as reported, NA if not applicable
  Baseline SE                                                                                                       SE of the absolute baseline value                                                                                                                                                                                                                                                                                          SE as reported, NR if not reported
  Baseline SD                                                                                                       SD of the absolute baseline value                                                                                                                                                                                                                                                                                          SD as reported, NR if not reported
  Baseline CI type                                                                                                                                                                                                                                                                                                                                                                                                                              
  Baseline lower CI                                                                                                                                                                                                                                                                                                                                                                                                                             
  Baseline upper CI                                                                                                                                                                                                                                                                                                                                                                                                                             
  Baseline value normalized                                                                                         Baseline value converted into normalized baseline units                                                                                                                                                                                                                                                                    Still insert value here report if normalized units are the same as the reported units
  Baseline value unit normalized                                                                                    Normalized baseline value units                                                                                                                                                                                                                                                                                            See assessments and conventions sheet for normalized assessment standard
  Baseline SE normalized                                                                                            Standard error of normalized baseline value                                                                                                                                                                                                                                                                                SE in the same units as normalized baseline, may need to be calculated from SD and *N*; if not provided, NA
  Baseline SD normalized                                                                                            Standard deviation of normalized baseline value                                                                                                                                                                                                                                                                            SD in the same units as normalized baseline, may need to be calculated from SE and *N*; if not provided, NA
  Baseline CI type normalized                                                                                                                                                                                                                                                                                                                                                                                                                   
  Baseline lower CI normalized                                                                                                                                                                                                                                                                                                                                                                                                                  
  Baseline upper CI normalized                                                                                                                                                                                                                                                                                                                                                                                                                  
  Baseline *N*                                                                                                      Number of patients from which the baseline value is derived                                                                                                                                                                                                                                                                Integer
  Baseline value comment                                                                                            Comment pertaining to the baseline value that cannot be dealt by other variables                                                                                                                                                                                                                                           e.g., the baseline value is the mean of last 7 days of the run in period
  **Reference specifications**                                                                                                                                                                                                                                                                                                                                                                                                                  
  **Repository**                                                                                                    **Description**                                                                                                                                                                                                                                                                                                            **Data entry standards**
  Ref code                                                                                                          Numerical code assigned for the literature citation. Maps the record to the assessment details                                                                                                                                                                                                                             Integer
  Protocol or trial number                                                                                          Protocol ID or the number of the trial report                                                                                                                                                                                                                                                                              As reported, NA if not applicable
  Date modified                                                                                                     Date of initial entry or subsequent modification of the data point                                                                                                                                                                                                                                                         mmddyy format
  Modified by                                                                                                       Initials of curator                                                                                                                                                                                                                                                                                                         
  Modification comment                                                                                              Any comment that is relevant to modification by the curator                                                                                                                                                                                                                                                                Initial entry if new record, brief statement of change(s)
  Copyright status                                                                                                  Provided by the client or procured by the service provider                                                                                                                                                                                                                                                                 Client provided or yes in case the manuscript is procured by the service provider
  Author                                                                                                            Authors of publication                                                                                                                                                                                                                                                                                                     As reported
  Journal                                                                                                           Journal name                                                                                                                                                                                                                                                                                                               Standard abbreviated forms can be used, generally as in the PubMed
  Publication year                                                                                                  Year of the publication                                                                                                                                                                                                                                                                                                    Integer
  Title                                                                                                             Title of the study                                                                                                                                                                                                                                                                                                          
  Volume                                                                                                            Volume number of the publication                                                                                                                                                                                                                                                                                           e.g., 180
  Pages                                                                                                             Page numbers of the publication                                                                                                                                                                                                                                                                                            e.g., 1--24
  Trial name alias                                                                                                  Trial name that trial is commonly referred to                                                                                                                                                                                                                                                                              NR if not reported
  Inclusion description                                                                                             Provide description of inclusion criteria                                                                                                                                                                                                                                                                                  Can be cut and paste from PDF, can be placed in an attached note
  Exclusion description                                                                                             Provide description of exclusion criteria                                                                                                                                                                                                                                                                                  Can be cut and paste from PDF, can be placed in an attached note
  Study design                                                                                                      Brief description of the study design                                                                                                                                                                                                                                                                                      Parallel-fixed arm, dose escalation, effect titration, crossover, etc.
  Location of the trial                                                                                             Geographical location where the study is conducted                                                                                                                                                                                                                                                                         Primary nationalities list
  Number of countries                                                                                               Number of countries the study is conducted                                                                                                                                                                                                                                                                                 Integer
  Number of centers                                                                                                 Number of centers the study is conducted                                                                                                                                                                                                                                                                                   Integer
  Trial start date                                                                                                  Date when the trial started                                                                                                                                                                                                                                                                                                mmddyy format
  Trial end date                                                                                                    Date when the trial completed                                                                                                                                                                                                                                                                                              mmddyy format
  Placebo-controlled or active comparator                                                                           Was there a control group and was it placebo                                                                                                                                                                                                                                                                               PBO control/active comparator
  Active comparator therapy                                                                                         If this was an active comparator trial what was the comparator therapy                                                                                                                                                                                                                                                     e.g., PTH
  Percent randomized to placebo                                                                                     Percent of subjects in the trial who are randomized to placebo                                                                                                                                                                                                                                                             Integer
  Add-on/washout study                                                                                              Was the study drug added on to standardized background Rx, was background Rx washed out prior to starting primary Rx, or was standardized background therapy withdrawn once primary RX started                                                                                                                             Add-On, Washout, Replacement, None
  Study blind                                                                                                       Was the trial blinded for the treatment phase                                                                                                                                                                                                                                                                              Yes, double blind
  Number of arms                                                                                                    Number of treatment arms the patients are randomized to                                                                                                                                                                                                                                                                    Integer
  Arm description                                                                                                   Codes and description for arms                                                                                                                                                                                                                                                                                             0 = placebo and others in sequence
  Dose descriptions                                                                                                 Brief descriptions of the treatment drugs and the respective doses along with regimens received                                                                                                                                                                                                                            0 = placebo, 1 = metformin 10 mg QW...
  Dose ranging within study                                                                                         Does the trial contain at least two primary treatment arms where different dose strengths were administered                                                                                                                                                                                                                Yes, No. Placebo does not count as a dose strength
  Primary longitudinal data                                                                                         Were multiple time values reported for the primary assessment endpoint                                                                                                                                                                                                                                                     Yes, No.
  Active phase trial duration                                                                                       What was the duration of the active phase of the trial                                                                                                                                                                                                                                                                     Time, units, i.e., 3 weeks
  Steady state effect achieved?                                                                                     Does it appear that effect stabilized over time for primary endpoints                                                                                                                                                                                                                                                      Yes, No. Not clear
  Was there a lead-in phase?                                                                                        Was there a standardized lead-in phase in the study other than a simple screening visit                                                                                                                                                                                                                                    Yes, No
  Lead-in phase duration                                                                                            If so, what was the duration                                                                                                                                                                                                                                                                                               If yes, time, units, i.e., 6 months. If no, 0
  Was there a follow-up phase?                                                                                      Was there a standardized follow-up phase that at least some patients were enrolled in after the active phase ended                                                                                                                                                                                                         Yes, No
  Duration of follow-up phase                                                                                       If so, what was the duration                                                                                                                                                                                                                                                                                               If yes, time, units, i.e., 6 months. If no, 0
  Primary endpoint                                                                                                  What is the primary outcome or assessment reported in the trial                                                                                                                                                                                                                                                            e.g., HBA1C
  Secondary endpoints                                                                                                                                                                                                                                                                                                                                                                                                                           
  Other efficacy endpoints available                                                                                List of the other secondary efficacy or biomarker outcomes reported in the trial                                                                                                                                                                                                                                           e.g., HOMA
  Most frequent AEs (incidence)                                                                                     List the most frequently reported AE's                                                                                                                                                                                                                                                                                     e.g., vomiting, nausea, headache, dizziness
  Adverse events                                                                                                    Grade,%, *n* by group, treatments for AEs, hospitalizations secondary to AEs and overall, ICU admissions secondary to AEs and overall                                                                                                                                                                                       
  Median and mean if reported                                                                                       Progression-free survival and overall survival in months (TTPD, TTTF)                                                                                                                                                                                                                                                       
  Survival rates                                                                                                    Percent alive at *X* months                                                                                                                                                                                                                                                                                                 
  Response rates                                                                                                    At what time?                                                                                                                                                                                                                                                                                                               
  Toxicity                                                                                                          Number of individuals experiencing toxicity/treatment group                                                                                                                                                                                                                                                                 

Analysis plan
-------------

A PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagram will be developed based on the search strategy and eligibility assessment to show the flow of included and excluded studies. The descriptive statistics from each trial of patients with squamous cell carcinoma will be included and described. These variables will include treatment group, number of patients, mean age (standard deviation), number and percent male, number and percent with stage IV disease, overall survival, progression-free survival, toxicity, and quality of life.

A network diagram visually describing existing treatments for squamous NSCLC will be created after all eligible studies have been identified. However, some publications may not present data in a format that allows them to be included in the study despite otherwise meeting eligibility criteria (e.g., mixed populations not reported separately, mixed histologies not reported separately, mixed lines of therapy not reported separately). In the case of a disconnected network resulting from the absence of data for the appropriate patient population, authors of such articles will be contacted and asked to provide the needed data from their publications that would enable connection to the studied network.

The primary purpose of this study is to perform indirect and direct comparisons of GC + N versus all identified comparators for overall survival (OS) and progression-free survival (PFS). Individual hazard ratios (HR) or median time-to-event (median time) and 95% confidence intervals (90% or 99% confidence intervals will be converted to 95%) for overall survival will be included in the network meta-analysis using a Bayesian approach that ensures the preservation of randomization in the network \[[@B10]\]. The HR will be used as the primary unit of analyses to evaluate differences in effect size between treatment groups. Data for analysis will be extracted directly from the text of each eligible article, calculated from data included in the text, or extrapolated from the Kaplan-Meier plot according to the method of Parmar and colleagues \[[@B11]\]. Graphs and figures will be digitized using TechDig software and/or *xyscan* tool (Debian, Inc) if necessary, and digitized values will be extracted.

Heterogeneity will be explored by comparing the fixed and random effects models to ensure that the network has good properties. Additionally, heterogeneity will be explored by visual inspection of forest plots. The consistency assumption will be tested by examining network diagrams to identify any closed \"loops\" where inconsistencies can occur. When the network is complex with multiarm trials, the \"node-splitting\" approach defined by Dias and colleagues \[[@B12]\] will be used to identify inconsistencies. Density plots of the posterior samples from models based on direct, indirect, and mixed evidence will be compared. In addition, the heterogeneity parameters (variance and standard deviation) and goodness of model fit measures (residual deviance and deviance information criterion (DIC), a Bayesian criterion for model comparison) between the direct and indirect models will be compared.

OS and PFS data will be analyzed using a log transformation of the HR and treating this as a continuous outcome. For studies with median time information, we will also use log transformation of the median time and treat this as a continuous outcome in sensitivity analyses. HRs are preferred summary statistics to median time per Michiels and colleagues \[[@B13]\], and hence, the analysis will utilize HR data for the primary outcome measure.

Ideally, the literature will provide values for log (HR) and the standard error (SE) for log (HR). If the SE for log (HR) is not available, an attempt will be made to estimate the missing value from the SE for median time, assuming an exponential distribution of survival time and log (HR) = -log (median time ratio). Alternatively, an estimate of the SE for log (HR) will be made on the basis of the number of subjects with events as specified below:

1\. \"MedianTime\" will be converted into log (median time);

2\. The SE for log (median time) is estimated as (log(upper confidence limit) - log (lower confidence limit))/2/quantile (confidence level) if a treatment arm has non-missing value for all three variables;

3\. If confidence limit is missing, then the number of subjects with events can be used to estimate the standard error for log (median time) as 1/sqrt(*n*) for a treatment arm.

Individual odds ratios and/or toxicity rates for each grade 3--4 toxicity from each study will be included, respectively, in an NMA using a Bayesian approach that ensures the preservation of randomization in the network. Odds ratios will be calculated for studies reporting toxicity rates. Prior to creating the odds ratios, we will ensure that similar versions of toxicity scaling criteria have been used. Data for analysis will be directly extracted from the text of the article or calculated from data in the text.

A network meta-analysis of GC + N to all identified comparators will be conducted for health-related quality of life (HRQoL) measures (including EQ-5D and the Lung Cancer Symptom Scale (LCSS)) during and following therapy. The most common quality of life instruments as reported across studies will be analyzed. Initial analyses will be limited to those quality of life outcomes for which GC + N data are available. For each identified measure, a standardized mean difference in quality of life outcomes from each study will be included. First, the number of trials per HRQoL instrument will be determined. If the number of trials per HRQoL instrument is 2 or more, then these data will be analyzed. For each instrument, data will be assessed according to the guidelines for that particular instrument and then pooled across studies to determine the standardized mean difference.

A meta-regression will be conducted using the key covariates of patient age and stage of disease (percent of patients with stage IV), as these variables have prognostic value in squamous NSCLC. Additional covariates may be identified following the literature review and will be considered for inclusion in *post hoc* analyses to control for potential bias.

Sensitivity analyses
--------------------

We anticipate that some studies will not report all relevant data. In order that such studies can still be included in the analysis, we may consider imputing missing data using established methods as appropriate \[[@B14]\]. If imputation is made, the Bayesian model as described above will be used as the primary analysis and will be compared with analyses including the imputed values. Sensitivity analyses may be conducted to examine the effect of this method using an approach proposed by Carpenter and colleagues \[[@B15]\], which entails imputing missing data under a missing at random assumption, and then reweighting the imputed data to allow for non-random selection. Sensitivity analyses as outlined for OS and PFS will also be conducted for HRQoL; however, the use of disparate HRQoL instruments or assessment time points may result in an inability to evaluate the study endpoint. Sensitivity analyses will be performed to assess the robustness of the findings. At a minimum, the following analyses will be conducted if there are at least three studies available for analysis:

1\. Repeat the meta-analysis using a frequentist approach;

2\. HR only (primary aim) versus HR or median time;

3\. By geographical site of study enrollment;

a\. e.g., Western versus Eastern hemispheres

b\. e.g., Americas versus Europe versus Asia

4\. Limit to patients with stage IV disease;

5\. Direct comparisons only;

6\. By excluding phase II trials;

7\. By age---studies with a mean age over the age of 70;

8\. Limiting the analysis to high-quality studies (≥6) as determined by the PEDro scale;

9\. Removing studies considered to be biased according to the Cochrane Risk of Bias Tool.

Assessment of bias and study quality
------------------------------------

The risk of bias will be appraised using the Cochrane Risk of Bias Tool ( <http://www.cochrane-handbook.org>). This tool was developed specifically to assess the internal validity of RCTs. It consists of the following seven criteria: 1) randomization generation, 2) allocation concealment, 3) blinding of outcome assessors, 4) blinding patients and personnel, 5) incomplete outcome data (i.e., withdrawals), 6) selective outcome reporting, and 7) other risks of bias. The final item will include fraudulent results, other methodological flaws in the RCTs, and the potential for bias.

To assess publication bias, the fail-safe *N* will be calculated. If the number of unpublished trials that may invalidate the findings is less than five, it will be noted in the conclusions as a potential limitation of the findings. If the number of unpublished trials to invalidate the findings is five or greater, it will be noted in the results. Furthermore, funnel plot analyses will also be conducted to provide a visual representation demonstrating where unpublished data may exist. This is planned to help guide the interpretation of the study findings and the direction of bias.

Quality of selected trials for inclusion in the review will be assessed. The PEDro quality scale, an 11-item scale designed for rating the methodological quality of randomized controlled trials \[[@B16]\], will be used to evaluate the quality of selected trials. Here the two reviewers will independently assess studies for methodological validity prior to inclusion. Identified studies that meet the inclusion criteria will then be grouped according to the class of statin used in the trial. High quality scores will be defined as a PEDro score ≥6 and low quality scores will be defined as a PEDro score \<6.

Missing data are expected in the majority of data fields collected in this meta-analysis. In cases of missing data, heterogeneity will be tested on all outcome variables to ensure that studies are comparable. Forest plots will be created for OS, PFS, toxicity, and quality of life endpoints. In the case of non-overlapping confidence intervals, the research team will discuss the need for *post hoc* subgroup analyses.

Discussion
==========

The study design for this systematic review and meta-analysis is presented here to follow PRISMA standards. Industry-sponsored or industry-led studies are increasingly under scrutiny regarding transparency and risk of bias \[[@B17]\]. This study protocol has been designed prior to any knowledge of the study data or outcomes from existing published literature and is being disseminated in an attempt to provide the scientific community with the ability to evaluate the methods and plans of our study before it is conducted. The study protocol has been designed to meet PRISMA standards \[[@B18],[@B19]\] and is being disclosed so that our methods can be retrieved and evaluated against the final analyses and interpretation of findings.

While it is almost impossible to fully anticipate the limitations of the data once they are obtained, this study has been designed in an attempt to pre-specify all primary analyses and sensitivity analyses to demonstrate the stability in results that may be discovered. However, it is possible that there will not be sufficient data to achieve all the pre-specified study aims or to complete all planned analyses. There are also possible limitations in the network connections. Unlike patients diagnosed with lung cancers of non-squamous histology, those with squamous NSCLC have not benefited from the same depth and breadth of research conducted to identify optimal treatment strategies. Therefore, via our search criteria, we are casting a wide net in the hopes of finding studies that not only investigate, but also report, outcomes for this histological subgroup.

Our ultimate goal is to provide reliable and trustworthy data regarding the comparative efficacy of necitumumab against other possible options for care so that decision makers can come to their own conclusions regarding the value of this molecule currently in development.
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